The Return of Psychedelics – How Psilocybin is Curing Treatment-Resistant Depression in Veterans.

A Marine veteran once lay on a couch wearing an eye mask, listening to music, and had what he later described as the most significant eight hours of his life in a room somewhere inside a Johns Hopkins research building. It was carpeted, softly lit, and had nothing clinical about it. It had been years since he had felt anything near normal. There had been three antidepressants that came and went. One made him dizzy, and another made him lose his appetite. After six weeks, he stopped taking the third because he claimed it made him feel like a ghost. Then someone gave him a psilocybin-containing pill.

Although it would be tempting to refer to this as a miracle story, doing so would be detrimental to the expanding body of scientific evidence supporting it. Research from Johns Hopkins, COMPASS Pathfinder’s phase 2 clinical trials, and a few other institutions points to something more measured but genuinely striking: psilocybin, the active ingredient in so-called magic mushrooms, seems to work in ways that mainstream psychiatry is just starting to understand for a significant portion of people whose depression has resisted every conventional treatment thrown at it.

It is difficult to ignore the Johns Hopkins data. In a follow-up study that was published in the Journal of Psychopharmacology in February 2022, researchers monitored 27 individuals with a history of depression who had undergone structured psychotherapy in addition to two doses of psilocybin. At 12 months, 58% were in complete remission and 75% demonstrated a significant response to treatment. These are not fringe experiment numbers. These are the numbers of something that merits careful consideration.

For reasons that seem both clear and painful, veterans are at the center of this discussion. For years, the suicide rate among American veterans has stubbornly remained higher than that of the general population. Military and mental health organizations frequently point to this statistic and seem powerless to alter it. An alarming percentage of patients do not respond well to standard antidepressants. By the time a patient has completed three or four rounds of antidepressant therapy, the remission rate has dropped to about 13%, according to the seminal STAR*D trial. That’s the demographic that psilocybin is intended to help—the people for whom the current system has essentially run out of solutions.

The nature of the experience itself is what makes psilocybin unique and why it differs greatly from recreational use in a clinical setting. Unlike an SSRI, it does more than just lessen symptoms. Participants in these trials frequently describe a psychological unpacking that feels more like years of therapy crammed into one afternoon than medication. Researchers think this is related to how psilocybin affects the brain’s default mode network, which is the circuitry linked to self-referential thought and, in depression, a persistent, inward-spiraling rumination. It seems as though the compound momentarily breaks those patterns, opening a window for the processing of previously stored emotional information in a different way.

A more cautious picture was presented by the November 2022 NEJM trial. A single 25-mg dose significantly reduced depression scores at three weeks compared to the 1-mg control group in a phase 2 double-blind study involving 233 participants. However, there was no statistically significant difference at the 10-mg dose. Suicidal thoughts were noted in all dose groups, and 77% of participants experienced adverse events, such as headaches, nausea, and dizziness. In contrast to the two-session protocols employed in other studies, it is still unknown if psilocybin’s benefits persist at twelve weeks with a single dose. Though not yet complete, the science shows promise.

The therapeutic environment may be just as important as the compound itself, especially for veterans. Psilocybin sessions are combined with extensive preparatory work in some of the most compelling veteran-focused programs. This helps participants understand what might surface, build trust, and establish context. It looks like that structure is working hard. Without that scaffolding, psilocybin alone might result in something much less dependable.

As expected, the legal system is lagging. Although Oregon and Colorado have started to establish pathways for supervised therapeutic use, psilocybin is still classified as a Schedule I controlled substance under federal law. Reclassification is gaining traction in Washington, but it seems to be moving slowly compared to the urgency of the veterans’ mental health crisis.

It’s difficult to watch this develop without experiencing a mix of cautious optimism and frustration: optimism because the evidence is actually mounting, and frustration because the majority of those who need these treatments are still waiting. Science is advancing more quickly than the systems designed to deliver it. For the time being, it’s unclear—and uncomfortable—if those systems will catch up before another generation of veterans runs out of options.